EGFR and non-small cell lung carcinoma: (43) identified EGFR mutations in 54 paired BMs and primary tumors of NSCLC in synchronous and metachronous BM patients using next-generation sequencing (NGS), the BM/primary concordance rate was 92% (Cohen’s κ coefficient, 0.799), and concordance of patients with mutated EGFR was 85.2% (23/27).